



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: October 23, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,

Subject: Press Release- Supriya Lifescience Ltd. signs agreement with Kalinga Institute of Technology for development of first-of-its-kind novel oral cancer detection kit

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release “Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for development of first-of-its-kind novel oral cancer detection kit”.

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for development of first-of-its-kind novel oral cancer detection kit

- The development of oral cancer detection kit is in line with Supriya Lifescience's vision of manufacturing niche products and becoming an innovation-led global CDMO player.
- **Quickblue** – Oral cancer detection kit helps patients detect cancer cells within minutes as against current conventional methods of biopsy & others.
- This product is not only a cheaper option but also found very sensitive detector. The global cancer market is estimated at USD21.5 bn and the company is expecting to create a 1-2% market share.

Mumbai, October 23, 2023: Supriya Lifescience Ltd, the Mumbai-based and one of the prominent specialized active pharmaceutical ingredients (API) manufacturing Company, has collaborated with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop one of its kind oral cancer detection kit named **Quickblue oral kit**.

This oral cancer detection kit is designed to detect oral cancer in a cost-effective and efficient manner. This kit seamlessly detects oral cancer and could potentially reduce the need for extensive preclinical and clinical trials. The company has also filed for the patent of the Quickblue oral kit.

Dr Satish Wagh, Chairman, Supriya Lifescience Ltd, estimates that the Quickblue oral kit could reduce the cost of oral cancer detection significantly, eliminating the need for multiple biopsies in cases of non-healing oral ulcers.

"The high prevalence of oral cancer, with millions of cases reported globally, underscores the importance of early detection. This product is particularly relevant in India and the Asian sub-continent, where a significant percentage of oral cancer patients are found."

"Early detection of cancer is crucial for improving treatment outcomes, and the Quickblue oral kit can contribute to saving lives by identifying oral cancer at an early stage. The development of the Quickblue oral kit is a promising advancement in the field of healthcare, with the potential to make oral cancer detection more accessible, cost-effective, and lifesaving. It addresses a critical healthcare need and underscores the importance of innovation in the pharmaceutical and healthcare industry."

Dr. Wagh also mentions, "The development of an oral cancer detection kit is in line with Supriya Lifescience's vision of manufacturing niche products to meet unmet medical needs. This initiative represents a step towards diversifying the product portfolio of Supriya Lifescience Ltd. The company aims to expand and scale to new heights over the next decade."

Commenting on the development of Quickblue, **Dr Mrutyunjay Suar, Director General R&D and Innovation, Kalinga Institute of Industrial Technology (KIIT) University**, said, “We are extremely proud to be part of this journey of collaborating with Supriya Lifescience Ltd for such a novel product. KIIT is committed to high-quality research and provides outstanding facilities and a supportive environment for our academics and students. KIIT’s research portfolio extends across many different areas including, biotechnology, medicine; rural management; physical activity and nutrition; education; and social and mental health. KIIT has placed much emphasis on creating enabling infrastructure and facilities for advanced research in diverse areas. Our research groups of scholars and faculty members worked relentlessly with the expert team of Supriya Lifescience to develop this product. We believe this product can be a lifesaver by early detection of oral cancer.”

About Supriya Lifescience Ltd:

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by the USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and is headquartered in Mumbai, India.

Backed by strong R&D, 14 active USDMFs, 8 active CEPs and worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company’s focus is to develop APIs and Intermediates for both Innovators and generic companies and we also partner exclusively as CDMO.

For more details:

Supriya Lifescience Ltd	Dentsu Creative PR
Krishna Raghunathan	Abhishek Chawande
T: 022-4033 2749	M: 9664516774
e-mail: cfo@supriyalifescience.com	e-mail: abhishek.chawande@dentsu.com